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To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of
Creutzfeldt–Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential
diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance
centres over the last years raises the concern of declining specificity due to higher number of cerebrospinal fluid tests performed
in various neurological conditions. Within the framework of a European Community supported longitudinal multicentre study
(‘cerebrospinal fluid markers’) we analysed the spectrum of rapid progressive dementia diagnoses, their potential influence on
14-3-3 specificity as well as results of other dementia markers (tau, phosphorylated tau and amyloid-b1–42) and evaluated the
specificity of 14-3-3 in Creutzfeldt–Jakob disease diagnosis for the years 1998–2008. A total of 29 022 cerebrospinal fluid sam-
ples were analysed for 14-3-3 protein and other cerebrospinal fluid dementia markers in patients with rapid dementia and
suspected Creutzfeldt–Jakob disease in the participating centres. In 10 731 patients a definite diagnosis could be obtained.
Protein 14-3-3 specificity was analysed for Creutzfeldt–Jakob disease with respect to increasing cerebrospinal fluid tests per year
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and spectrum of differential diagnosis. Ring trials were performed to ensure the comparability between centres during the
reported time period. Protein 14-3-3 test specificity remained high and stable in the diagnosis of Creutzfeldt–Jakob disease
during the observed time period across centres (total specificity 92%; when compared with patients with definite diagnoses
only: specificity 90%). However, test specificity varied with respect to differential diagnosis. A high 14-3-3 specificity was
obtained in differentiation to other neurodegenerative diseases (95–97%) and non-neurological conditions (91–97%). We
observed lower specificity in the differential diagnoses of acute neurological diseases (82–87%). A marked and constant
increase in cerebrospinal fluid test referrals per year in all centres did not influence 14-3-3 test specificity and no change in
spectrum of differential diagnosis was observed. Cerebrospinal fluid protein 14-3-3 detection remains an important test in the
diagnosis of Creutzfeldt–Jakob disease. Due to a loss in specificity in acute neurological events, the interpretation of positive
14-3-3 results needs to be performed in the clinical context. The spectrum of differential diagnosis of rapid progressive de-
mentia varied from neurodegenerative dementias to dementia due to acute neurological conditions such as inflammatory dis-
eases and non-neurological origin.
Keywords: rapid dementia; Creutzfeldt–Jakob disease; cerebrospinal fluid; 14-3-3; specificity; neurodegeneration; differential
diagnosis in dementia
Introduction
The clinical diagnosis of Creutzfeldt–Jakob disease is based on
clinical syndrome and results of established paraclinical tests
(EEG, CSF analysis and cranial MRI) (Zerr et al., 2000a, 2009;
Collins et al., 2006). The predominant clinical symptoms are char-
acterized by rapid progressive dementia followed by development
of neurological signs, e.g. ataxia and myoclonus (Gambetti et al.,
2003). The disease is fatal and leads to death in a few months.
Detection of periodic sharp wave complexes on EEG substan-
tiated the diagnosis of sporadic Creutzfeldt–Jakob disease for a
long period of time (Masters et al., 1979; Zerr et al., 2000a, b).
From 1995 onwards, detection of neuronal destruction markers in
CSF have become more and more important. They have been
established in diagnostic work-up, with protein 14-3-3 as the
most promising surrogate marker finally included in the WHO
criteria (Hsich et al., 1996; Zerr et al., 2000a). Because elevated
levels of protein 14-3-3 are also reported in a range of
non-prion-related diseases, mostly caused by an acute neurological
event such as encephalitis, stroke, epileptic fit or tumour, positive
results must be interpreted in the clinical context.
Another major step in the diagnosis of sporadic Creutzfeldt–
Jakob disease was the introduction of MRI, where a specific pat-
tern in patients with sporadic Creutzfeldt–Jakob disease, charac-
terized by hyperintense signals in basal ganglia and cortical
regions, was identified (Tschampa et al., 2007; Meissner et al.,
2008). Especially sensitive MRI techniques such as FLAIR and
diffusion-weighted MRI sequences allow a diagnosis of sporadic
Creutzfeldt–Jakob disease with high sensitivity and specificity
(Satoh et al., 2007; Meissner et al., 2009). As a result, a positive
MRI scan was proposed to be included into the clinical criteria in
2009 (Zerr et al., 2009).
To date, CSF analysis, in particular protein 14-3-3 testing, presents
an important approach in the identification of Creutzfeldt–Jakob
disease cases and a request for CSF testing to specialized laboratories
is frequently a major way to obtain referrals to surveillance centres.
However, one special point of criticism of 14-3-3 testing was a po-
tential loss of specificity and several reports on that have been
published (Chohan et al., 2010; Coulthart et al., 2011; Perry and
Geschwind, 2011). Within the framework of a European
Community (EC) supported longitudinal multicentre study (‘CJD
markers’) we evaluated the specificity of 14-3-3 in Creutzfeldt–
Jakob disease diagnosis from the years 1998–2008. In addition we
analysed the spectrum of rapid progressive dementia diagnoses,
their potential influence on 14-3-3 specificity as well as results of
related dementia markers (tau, phosphorylated tau, amyloid b1–42)
in different forms of rapid dementias. We present results of regular
ring trials conducted in participating surveillance laboratories to ana-
lyse inter-laboratory reliability (Supplementary material).
The term ‘rapid progressive dementia’ or shortened ‘rapid de-
mentia’ we used in this study summarizes a condition of cognitive
deterioration that can be attributed to either a neurological (most
commonly neurodegenerative) or non-neurological disease
(Geschwind et al., 2008). Potentially reversible conditions (e.g.
acute delirium, pseudo-dementia in depression, CNS inflammation)
can appear frequently and need to be considered in the diagnostic
process.
Materials and methods
Patients
The study was conducted within the framework of an EC-supported
multinational study (‘CJD markers’) (Sanchez-Juan et al., 2006).
Patients were referred to national surveillance units for detection of
CSF 14-3-3 protein during the course of routine clinical diagnosis and
surveillance. Samples were sent to the individual laboratories for the
detection of CSF 14-3-3, further for CSF tau, phosphorylated tau and
amyloid b1–42 in participating countries between 1998 and 2008. All
countries collected clinical and neuropathological data from those pa-
tients with a clinical suspicion of Creutzfeldt–Jakob disease or related
disorders. The corresponding diagnoses were obtained by follow-up.
Patient’s data collection and analysis
Clinical data such as age at onset, gender, disease duration, time point
of lumbar puncture, final clinical and neuropathological diagnoses
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were collected by each centre. A database was set up, which included
detailed data on the CSF markers and patients’ characteristics for a
total of 29 022 samples from patients with Creutzfeldt–Jakob disease
and non-Creutzfeldt–Jakob disease (other rapid dementia) diagnoses.
In 10 731 patients, a definite diagnosis could be obtained. From the
remaining 18 291 samples, no further clinical data were available. In all
participating centres, the diagnosis of Creutzfeldt–Jakob disease was
made according to established, internationally agreed criteria (WHO,
1998; Zerr et al., 2009).
Control patients were those who proved an alternative diagnosis or
in whom Creutzfeldt–Jakob disease was definitely excluded on clinical
or pathological grounds. Diagnoses in control patients were based on
neuropathology (whenever possible) and clinical follow-up
information.
For calculation of 14-3-3 specificity we used a two-step approach:
(i) analysis was restricted to patients with a definite diagnosis
(n = 10 731) and (ii) total specificity was calculated using all available
samples. When a clinical diagnosis was available, patients were as-
signed to one of the following groups: neurodegenerative, inflamma-
tory, CNS tumour/paraneoplastic, stroke, psychiatric, metabolic and
‘other’ (Table 1).
Cerebrospinal fluid protein analysis
CSF was taken by lumbar puncture during the clinical investigation of the
patient at the notifying hospital and sent to individual laboratories. Tests
were conducted in each laboratory according to common agreed stand-
ards. CSF was stored at 80C prior to analysis. CSF was analysed for
14-3-3, tau, phosphorylated tau and amyloid-b1–42 according to estab-
lished protocols. Test results were entered into the database.
Protein 14-3-3 analysis
Protein 14-3-3 was tested in CSF by western blot according to previ-
ously published protocols (Hsich et al., 1996; Zerr et al., 1998). Each
western blot was analysed with a semi-quantitative method (nega-
tive = no signal/band present, positive = strong signal/band present,
trace = weak signal/band present). Each blot was run with a positive
and negative control. As a positive standard, recombinant 14-3-3
[14-3-3 beta protein (human), AbFrontier Co., Ltd] was used.
Tau
CSF tau protein was quantitatively analysed using a commercially
available ELISA kit according to manufacturer’s instruction
(INNOTEST hTAU Ag, Innogenetics). A positive tau-test for
Creutzfeldt–Jakob disease was considered at a cut-off level
41300 pg/ml (Otto et al., 2002; Sanchez-Juan et al., 2006)
Phosphorylated tau
Human tau, phosphorylated at Thr181 (phosphorylated tau) was mea-
sured quantitatively a with commercially available ELISA kit
[INNOTEST PHOSPHO-TAU(181P), Innogenetics]. A pathological
elevated phosphorylated tau level was considered at 461 pg/ml ac-
cording to manufacturer’s instruction, aimed at the diagnosis of
Alzheimer’s disease.
Amyloid b1–42
Amyloid b1–42 was detected with a commercially available ELISA kit
[INNOTEST ß- AMYLOID(1–42) Innogenetics] for quantitative ana-
lysis. A pathological decreased amyloid b1–42 assay was considered at
5450 pg/ml according to manufacturer’s instruction, aimed at the
diagnosis of Alzheimer’s disease.
Statistical analyses
Descriptive analyses as well as validity analysis were performed using
SPSS 19.0 (IBM SPSS Statistics 19). Reliability was estimated using
Stata 11 (StataCorp LP). Inter-laboratory reliability was assessed
using Cohen’s kappa for comparisons of two raters (data not
shown) and Fleiss’ kappa for comparisons of multiple raters.
Agreement was estimated according to Landis and Koch (1977):
perfect if kappa 40.8, substantial if 0.85 kappa4 0.6, moderate if
0.65 kappa4 0.4, fair if 0.45 kappa4 0.2, slight if 0.25 kappa
4 0, poor if kappa 50 (Supplementary material).
Results
In total, CSF analysis of dementia markers (14-3-3, tau, phos-
phorylated tau, amyloid b1–42) were performed on 29 022 sam-
ples. The main analysis (patient’s with definite clinical diagnosis)
comprised 3616 samples from patients with various forms of
transmissible spongiform encephalopathies (3254 samples being
from patients with sporadic Creutzfeldt–Jakob disease) and 7115
from control subjects (Table 1).
Diagnoses of rapid progressive
dementias in 14-3-3 test referrals
Table 1 demonstrates the rapid progressive dementia diagnoses in
patients with suspected Creutzfeldt–Jakob disease referred for CSF
protein 14-3-3 testing between the years 1998 and 2008.
Differential diagnoses were divided into: prion disorders
(n = 3616), primary and secondary forms of neurodegenerative
dementia (n = 3034, including vascular dementia and normal
Table 1 Diagnostic spectrum of rapid dementia in CSF
biomarkers from patients with definite clinical/neuro-
pathological diagnosis
Diagnosis n (%)
Sporadic Creutzfeldt–Jakob disease 3254 (30.3)
Genetic Creutzfeldt–Jakob disease 229 (2.1)
Iatrogenic Creutzfeldt–Jakob disease 46 (0.4)
Variant Creutzfeldt–Jakob disease 27 (0.3)
Gerstmann–Stra¨ussler–Scheinker disease 17 (0.2)
Fatal Familial Insomnia 43 (0.4)
Neurodegenerative 3034 (28.3)
Inflammation 794 (7.4)
Paraneoplastic/CNS tumour 346 (3.2)
Stroke 583 (5.4)
Epileptic fit 218 (2.0)
Psychiatric 459 (4.3)
Metabolic 483 (4.5)
Other 1198 (11.2)
Total 10 731 (100.0)
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pressure hydrocephalus) and acute neurological disorders such as
stroke, CNS inflammation, CNS tumour or epileptic fit (n = 1941).
Non-neurological causes were from psychiatric (e.g. pseudo-
dementia in depression) or metabolic origin (e.g. hyponatraemia)
or related to ‘other diagnosis’ (n = 2140). The most frequent dif-
ferential diagnosis was sporadic Creutzfeldt–Jakob disease with
30.3%, followed by neurodegenerative dementia with 28.3%
and patients with ‘other diagnosis’ (11.2%). Regarding acute
neurological disorders, the group of CNS inflammation was most
frequent with 7.4%, followed by stroke (5.4%) and paraneoplas-
tic/CNS tumour (3.2%). Rapid cognitive disturbance from a
non-neurological cause comprised 4.3% psychiatric and 4.5%
metabolic origin. If we exclude all patients with transmissible
spongiform encephalopathies from the analysis, the distribution
was as follows: 42.6% neurodegenerative dementia, 27.3%
acute neurological disease (most frequently: 11.2% CNS inflam-
mation, 8.2% stroke) and 13.2% non-neurological, potentially
treatable cognitive deterioration (6.8% metabolic and 6.4% psy-
chiatric disease).
Cerebrospinal fluid dementia markers
in rapid progressive dementias
In the individual reference laboratories we observed a trend towards
increased 14-3-3 test referrals not only for Creutzfeldt–Jakob
disease, but also in screening of CSF dementia markers in patients
with rapid progressive dementia (Fig. 1A). Going along with this
finding, we observed a decrease in our positive predictive values
over time. The negative predictive value remains stable (Fig. 1C)
Because of this trend, we were able to collect substantial data on
dementia markers in these patients. Hereby, we analysed tau, phos-
phorylated tau and amyloid-b1–42 according to subgroups of neu-
rodegenerative, acute neurological or non-neurological (potentially
reversible) origin in a similar fashion to 14-3-3.
Table 2 summarizes collective data on 14-3-3, tau, phosphory-
lated tau and amyloid-b1–42. As previously described, 14-3-3 was
negative in 93% of all patients with neurodegenerative disorders.
The test became more often false positive in acute neurological
events (inflammation 19.2%, stroke 15.2%, epileptic fits 17% and
CNS tumour 18.4%) causing a drop in specificity than neurode-
generative and non-neurological forms of dementia. With respect
to tau we observed a similar trend. Levels at a cut-off 41300 pg/
ml are considered highly suggestive for Creutzfeldt–Jakob disease
(Otto et al., 2002; Sanchez-Juan et al., 2006) and were referred
to as ‘tau positive’ in our analysis. ‘Tau negative’ results were
obtained in 95% of all neurodegenerative diseases. ‘Tau positive’
results were similarly obtained as 14-3-3 in patients with epileptic
fits (24%), CNS tumour/paraneoplastic (22%) and stroke
(18.4%).
For phosphorylated tau and amyloid-b1–42 no particular cut-off
points are established in Creutzfeldt–Jakob disease diagnosis. For
Figure 1 (A) Total CSF samples tested by years [blue = no transmissible spongiform encephalopathy (TSE) diagnosis; red = transmissible
spongiform encephalopathy diagnosis] from all participating countries. (B) Protein14-3-3 specificity and sensitivity by years. (C)
Protein14-3-3 positive and negative predictive values (PPV/NPV) by years. Of note, decrease in positive predictive values following the
increasing numbers of patients with non-transmissible spongiform encephalopathies tested. Negative predictive value remains stable.
3054 | Brain 2012: 135; 3051–3061 K. Stoeck et al.
this reason calculation of ‘false positive’ or ‘false negative’ results
in the differentiation of Creutzfeldt–Jakob disease from other rapid
dementia diagnoses was not possible. However patients with low
amyloid-b1–42 and high phosphorylated tau levels are at a clear
risk of Alzheimer’s disease (Hertze et al. 2010). We observed a
pathologically elevated phosphorylated tau median in the group
with epileptic fits (64.5 pg/ml) only. For amyloid-b1–42, we found
pathologically decreased levels in the group of neurodegenerative
CNS diseases (413 pg/ml). This was expected as it represents a
typical result in patients with Alzheimer’s disease (see later). Of
interest, in non-neurological patients with the diagnosis ‘metabolic
disorders’ we also detected decreased median levels of
amyloid-b1–42 (418 pg/ml).
Cerebrospinal fluid dementia
markers in neurodegenerative
diseases, vascular dementia and
normal pressure hydrocephalus
As predetermined cut-off values are not available for the major-
ity of differential diagnoses in this study, the next analysis de-
scribes results of CSF dementia marker profiles in various
neurodegenerative dementias. Data on CSF dementia markers
(14-3-3, tau, phosphorylated tau and amyloid-b1–42) were eval-
uated in a total of 3034 patients (28.3% of the total group) with
a neurodegenerative disease diagnosis. Out of these patients,
941 (37.4%) displayed a diagnosis of Alzheimer’s disease, fol-
lowed by 486 patients (19.3%) with unclassified dementia, 362
patients with Lewy body disease (14.4.%), 172 patients with
vascular dementia (6.8%), 162 patients with frontotemporal de-
mentia (6.4%), 142 patients with Parkinson’s disease (5.6%), 74
patients with multisystem atrophy (2.9%), 62 patients with pro-
gressive supranuclear palsy (2.5%), 57 patients with corticobasal
degeneration (2.3%), 33 patients with Huntington’s disease
(1.3%), 16 patients with normal pressure hydrocephalus
(0.6%) and 10 patients with motor neuron disease (0.4%)
(Fig. 2).
A positive 14-3-3 test was seen in patients with vascular de-
mentia (10.7%) followed by Alzheimer’s disease (5.8%) and Lewy
body disease (5.3%) (Table 3). A ‘positive tau’ (at Creutzfeldt–
Jakob disease cut-off 41300 pg/ml) was obtained in vascular de-
mentia (7.8%), Alzheimer’s disease (7.6%), Parkinson’s disease
(2.0%) and Lewy body disease (1.8%) (Table 4). The median
tau ranged highest in the group of Alzheimer’s disease
(314 pg/ml) and Huntington’s disease (383 pg/ml) followed by
vascular dementia (206 pg/ml) and Lewy body disease (216 pg/
ml) (Table 5). Median phosphorylated tau levels of other neuro-
degenerative dementias ranged at normal levels; however, all
neurodegenerative disease groups displayed pathologically ele-
vated phosphorylated tau levels at maximum range. For
amyloid-b1–42, pathologically decreased levels (5450 pg/ml)
were observed in Alzheimer’s disease (median 404 pg/ml), Lewy
body disease (336 pg/ml) and Huntington’s disease (321 pg/ml)
(Table 5).
To illustrate our findings, we have grouped diseases according
to similar pathology: (i) Alzheimer’s disease, (ii) vascularT
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dementia, (iii) -synucleinopathies including Parkinson’s disease,
Lewy body disease and multisystem atrophy and (iv) tauopa-
thies including frontotemporal dementia and progressive supra-
nuclear palsy (Fig. 3A–C). Here we can show that median levels
of tau and phosphorylated tau generally range higher in
Alzheimer’s disease, vascular dementia and Lewy body disease
whereby in contrast, median levels of amyloid-b1–42 are gener-
ally reduced in patients with Alzheimer’s disease and patients
Figure 2 Distribution of neurodegenerative dementia diagnosis. AD = Alzheimer’s disease; CBD = corticobasal degeneration;
FTD = frontotemporal dementia; HD = Huntington’s disease; LBD = Lewy body disease; MND = motor neuron disease;
MSA = multisystem atrophy; PD = Parkinson’s disease; PSP = progressive supranuclear palsy; NPH = normal pressure hydrocephalus;
VD = vascular dementia.
Table 3 Results of positive 14-3-3 tests in neurodegenerative dementia (excluding Creutzfeldt–Jakob disease)
Protein 14-3-3
Diagnosis Total n Negative (%) Positive (%) Trace
(%)
Alzheimer’s disease 932 851 (91.3) 54 (5.8) 27 (2.9)
Vascular dementia 169 144 (82.5) 18 (10.7) 7 (4.1)
Lewy body disease 358 331 (92.5) 19 (5.3) 8 (2.2)
Frontotemporal dementia 162 150 (92.6) 7 (4.3) 5 (3.1)
Motor neuron disease 10 10 (100) 0 (0) 0 (0)
Multisystem atrophy 74 68 (91.6) 2 (2.7) 4 (5.4)
Corticobasal degeneration 57 56 (98.2) 1 (1.8) 0 (0)
Huntington’s disease 32 32 (100) 0 (0) 0 (0)
Normal pressure hydrocephalus 16 15 (93.8) 0 (0) 1 (6.3)
Parkinson’s disease 140 134 (95.7) 6 (4.3) 0 (0)
Progressive supranuclear palsy 62 60 (96.8) 2 (3.2) 0 (0)
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with Lewy body disease when compared with other disease
groups here.
Cerebrospinal fluid test referrals
per year
We observed a constant increase in CSF test referrals per
year between 1998 and 2008 that was seen in all participating
countries (Fig. 1A). In spite of the increase in CSF tests, there was
no increase in the total number of cases with identified transmis-
sible spongiform encephalopathies. In the years 1998–2005 we
identified between 330 and 422 cases with transmissible spongi-
form encephalopathies per year. Between 2005 and 2008, the
number of cases with transmissible spongiform encephalopathies
appeared reduced (139–194 cases per year), because collective
data was not available from all participating countries during this
time period.
Cerebrospinal fluid 14-3-3 specificity in
sporadic Creutzfeldt–Jakob disease
Despite of the increasing number of CSF referrals per year for
detection of 14-3-3 in suspected cases of Creutzfeldt–Jakob dis-
ease in the 10-year period, we calculated a stable and high spe-
cificity of 14-3-3 that ranged from 0.91 to 0.95 per year (Fig. 1B).
The total 14-3-3 specificity for Creutzfeldt–Jakob disease during
the observed time period was 0.92. When compared with all pa-
tients with definite diagnoses only, the specificity was slightly
lower (0.90).
Influence of 14-3-3 specificity by
differential diagnosis
The overall test specificity varied with respect to differential diag-
nosis. A lower 14-3-3 specificity was observed in discrimination to
acute neurological events (82–87%), a high 14-3-3 specificity was
obtained in neurodegenerative diseases (95–97%) and
non-neurological conditions (91–97%) (Fig. 4 and Table 6).
Discussion
Rapid progressive dementia diagnosis
The spectrum of differential diagnosis of rapid dementia ranged
from neurodegenerative, acute neurological (e.g. CNS inflamma-
tion, tumour, stroke) and non-neurological (e.g. psychiatric, meta-
bolic) origin. The most frequent neurodegenerative disease
diagnoses in our cohort were Alzheimer’s disease, Lewy body dis-
ease and vascular dementia. This follows a similar trend when
compared to previous reports from longitudinal national surveil-
lance studies (Van Everbroeck et al., 2004; Heinemann et al.,
2007; Josephs et al., 2009; Chitravas et al., 2011). Likewise, we
observed a significant ratio of potentially treatable forms of rapid
dementia diagnoses that were previously identified as important
differential diagnoses of suspected transmissible spongiform ence-
phalopathies (Chitravas et al. 2011).
Table 5 Overview on levels of tau, phosphorylated tau and amyloid b1–42 in neurodegenerative dementia (excluding
Creutzfeldt–Jakob disease)
Diagnosis Tau (pg/ml) Phosphoylated tau (pg/ml)* Amyloid b1–42 (pg/ml)*
Total n Median (min–max) Total n Median (min–max) Total n Median (min–max)
Alzheimer’s disease 132 314 (75–8766) 51 83 (19–202) 108 404 (80–1445)
Vascular dementia 64 206 (75–4878) 25 49 (17–110) 147 490 (80–1481)
Lewy body disease 55 214 (75–1395) 35 54 (10–182) 327 336 (89–1450)
Frontotemporal dementia 28 159 (70–554) 16 39 (18–105) 146 497 (110–865)
Multiple system atrophy 15 136 (70–740) 7 41 (17–72) 67 481 (93–852)
Corticobasal degeneration 4 219 (164–389) 3 60 (53–65) 54 457 (282–549)
Huntington’s disease 4 383 (75–933) 3 31 (20–123) 30 321 (222–1419)
Parkinson’s disease 51 179 (0–756) 37 55 (17–106) 105 476 (80–1304)
Progressive supranuclear palsy 11 131 (75–275) 9 38 (11–69) 53 524 (77–756)
Table 4 Results of positive tau tests (41300pg/ml) in
neurodegenerative dementia (excluding Creutzfeldt–Jakob
disease)
Tau (cut-off 41300 pg/ml)
Diagnosis Total
(n)
Negative
(%)
Positive
(%)
Alzheimer’s disease 132 122 (92.4) 10 (7.6)
Vascular dementia 64 59 (92.2) 5 (7.8)
Lewy body disease 55 54 (98.2) 1 (1.8)
Frontotemporal dementia 28 28 (100) 0 (0)
Motor neuron disease 1 1 (100) 0 (0)
Multiple system atrophy 15 15 (100) 0 (0)
Corticobasal degeneration 4 4 (100) 0 (0)
Huntington’s disease 4 4 (100) 0 (0)
Parkinson’s disease 51 50 (98) 1 (2)
Progressive supranuclear palsy 11 10 (90.9) 1 (9.1)
Other dementia 12 12 (100) 0 (0)
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Results of dementia markers in
neurodegenerative dementias and rapid
dementia from acute neurological
diseases
Many studies on amyloid b1–42, total tau levels and its phosphory-
lated isoforms have been performed in CSF biomarker-supported
diagnosis of Alzheimer’s disease. The combined measurement of
tau and amyloid b1–42 in CSF has proven diagnostic accuracy for
Alzheimer’s disease (Hulstaert et al., 1999). However, in most
studies, the number of patients per group is limited and various
criteria and diagnostic techniques have been applied (Zerr et al.,
2011). Amyloid b1–42 levels are decreased in patients with
Alzheimer’s disease, but might also decrease in other types of
dementia. Test sensitivity for amyloid b1–42 alone is given from
60–96%, depending on the design of the study (Zerr et al.
2011). Elevated levels of tau and phoshorylated tau are recognized
hallmarks in the CSF supported diagnosis of Alzheimer’s disease
Figure 4 Protein 14-3-3 specificity stratified by differential diagnosis (this includes total number of 14-3-3 tests in all countries all years).
See also Table 6.
Figure 3 (A) Boxplot of tau levels. (B) Boxplot of phosphorylated tau (P-Tau) levels. (C) Boxplot of amyloid-b1–42 levels in neurode-
generative dementia diagnosis. AD = Alzheimer’s disease; FTD = frontotemporal dementia; LBD = Lewy body disease; MSA = multisystem
atrophy; PD = Parkinson’s disease; PSP = progressive supranuclear palsy; VD = vascular dementia.
Table 6 Protein 14-3-3 specificity stratified by differential
diagnosis (this includes total number of 14-3-3 tests in all
countries all years)
Diagnostic category Negative/
trace (n)
Positive
(n)
Total
(n)
Specificity
Alzheimer’s disease 878 54 932 0.94
Lewy body dementia 339 19 358 0.95
Other neurodegenerative 1156 51 1207 0.96
Inflammatory 634 151 785 0.81
Paraneoplastic/CNS tumour 279 63 342 0.82
Stroke 487 87 574 0.85
Epileptic fit 181 37 218 0.83
Psychiatric 446 13 459 0.97
Metabolic 445 36 481 0.93
Other 1046 132 1178 0.89
No diagnosis 16 824 1248 18 072 0.93
Total 22 715 1891 24 606 0.92
See also Fig. 4.
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(Kapaki et al., 2007; Snider et al., 2009; Hertze et al., 2010;
Scheurich et al. 2010; van Harten et al., 2011).
Compared with Alzheimer’s disease, elevated tau or reduced
amyloid-b1–42 are usually not found in other forms of neurodegen-
erative dementia (e.g. tauopathies, vascular dementia, Lewy body
disease) (Grossman et al., 2005; Hu et al., 2010). A recent large US
cohort study analysed CSF dementia marker profiles on neurodegen-
erative dementia (Schoonenboom et al., 2012) and obtained similar
results as the study presented here. A profile as seen in Alzheimer’s
disease was detected in patients with Lewy body disease (47%),
corticobasal degeneration (38%), vascular dementia and frontotem-
poral dementia (both30%). When analysing median CSF levels for
tau and amyloid b1–42 alone, all above mentioned groups ranged at
normal values, thus their findings are corresponding well to our re-
sults both in median levels and minimum/maximum values.
When focusing on CSF markers in rapid dementia of acute
neurological origin data in the literature are limited. As inflamma-
tory diseases are potentially treatable, the differential diagnosis of
this group is of special importance. With respect to the biomarker
profiles, these patients had less frequently increased tau levels in
CSF (8.6%) than a positive 14-3-3 test (19.2%). Thus, in particu-
lar circumstances, high 14-3-3 levels and at the same time low tau
levels in the CSF might be indicative for a potentially treatable
inflammatory or autoimmune mediated disorder.
Specificity of protein 14-3-3
A positive CSF 14-3-3 test displays one of the important diagnos-
tic tools in the identification of patients with Creutzfeldt–Jakob
disease at present because from technical point of view this
marker is stable and CSF samples can be forwarded for testing
to specialized laboratories. Meanwhile, the test is widely available
and serves as an important tool in surveillance studies worldwide.
Because test specificity was argued to be low based on single
centre reports and small selected cohorts, our goal was to analyse
14-3-3 specificity in a 10-year longitudinal multicentre study in a
large unbiased cohort of patients.
A large number of studies proved that in the appropriate clinical
circumstances a positive 14-3-3 test is highly sensitive and specific
for sporadic Creutzfeldt–Jakob disease diagnosis. Protein 14-3-3
detection correlated with clinical diagnosis in 85–94% in sporadic
Creutzfeldt–Jakob disease. Specificities ranging from 84% (Zerr
et al., 2000a) and 85% (Sanchez-Juan et al., 2007) to 100%
(immunoblot; Beaudry et al., 1999) and immunoassay (cut-off
48 ng/ml; Aksamit et al., 2001) have been reported. The majority
of studies on national and multicentre levels reported a 14-3-3
specificity 490% (Hsich et al., 1996; Zerr et al., 1998; Lemstra
et al., 2000; Van Everbroeck et al., 2003; Cuadrado-Corrales
et al., 2006; Green et al., 2007). However, with increasing num-
bers of test referrals per year, we observed that a number of
positive tests were related to non-Creutzfeldt–Jakob disease diag-
nosis mostly of acute neurological origin. This observation was
supposed to impact on previously reported high specificity and
subsequently led to question the value of this test in
Creutzfeldt–Jakob disease diagnosis (Perry and Geschwind 2011).
With our analysis we provide evidence that in spite of increasing
CSF tests per year—a phenomena experienced in all participating
countries—the specificity of 14-3-3 remained highly stable an
overall specificity of 92%. The number of patients with
Creutzfeldt–Jakob disease diagnosis increased with time after this
test became available but there was no further substantial increase
in numbers after 2000.
Rapid dementia caused by acute neurological events (e.g. in-
flammation, stroke, CNS tumour or epileptic fits) is the main
reason for a drop in test specificity from 92% to 82–85%. It is
not clear why such CSF samples were referred for 14-3-3 testing
since these conditions do not represent a Creutzfeldt–Jakob dis-
ease differential diagnosis. If tested in the context of neurodegen-
erative disease alone, the test specificity was high (95–97%).
A careful interpretation of a positive 14-3-3 test in the clinical
context is therefore mandatory to exclude acute neurological
events which is easily achieved taken together information on
basic CSF results (e.g. cell count, total protein and oligoclonal
bands) as well as imaging results (exclusion of tumour, encephalitis
and stroke) and EEG (epileptic pattern) together with the thorough
ascertainment of the patient’s clinical history.
Recent studies from UK and Canadian cohorts, however, re-
ported discrepant lower results on 14-3-3 specificities ranging
from 72% (Coulthart et al., 2011) to 74% (Chohan et al.,
2010). Previous studies, including an earlier analysis of our multi-
centre consortium, identified influencing parameters on 14-3-3
test specificity such as time point of CSF analysis during disease
course, thorough diagnostic work-up of related differential diag-
noses and PRNP 129 genotype (Zerr et al., 2000b; Sanchez-Juan
et al., 2006; Pennington et al., 2009). In this view, it is of con-
sideration whether the reported lower 14-3-3 specificities were
due to single centred cohorts or heterogeneous analysis of
14-3-3 results with regard to above mentioned influencing factors
(e.g. clarification/follow up of disease diagnosis or timing). Also
potential reasons might be differences in test methods (western
blot versus immunoassay), variations in test protocols and verifi-
cation of 14-3-3 results in ring trials in different centres.
In our study, we provide results on ‘total’ 14-3-3 specificity
calculated on almost 30 000 CSF analyses. For various reasons
(e.g. no information, patients lost at follow up and data protection
regulations), the final diagnosis was not always available. We are
aware that this might result in a selection bias in relation to the
patients where a diagnosis was achieved. On the other hand,
definite diagnoses of non-Creutzfeldt–Jakob disease cases in na-
tional reference centres are usually only obtained if the respective
patient is seriously suspected to suffer from Creutzfeldt–Jakob dis-
ease. This is much more likely, when 14-3-3 testing shows a
(false) positive result. The respective group with a definite diag-
nosis might therefore be even more prone to selection bias than a
control group including all patients reported to the reference cen-
tres. Therefore we provided all figures to demonstrate that speci-
ficity figures were not affected much by this approach (total
specificity 92%, in definite diagnoses specificity: 81–97%).
Conclusion
In conclusion, our multicentre longitudinal study demonstrates that
CSF protein 14-3-3 detection remains an important test in the
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diagnosis of Creutzfeldt–Jakob disease. Due to a loss in specificity
in acute neurological events, the interpretation of positive 14-3-3
results needs to be performed in the clinical context. The spectrum
of differential diagnosis of rapid progressive dementia included
those of neurodegenerative origin, dementia in acute neurological
diseases as well as from non-neurological origin. Thus, a thorough
clinical work-up of rapid dementia diagnosis should be performed
to identify their origin especially with regard of potentially treat-
able forms. CSF biomarkers are helpful in differentiation of rapid
dementia forms such as Creutzfeldt–Jakob disease, but also in solid
identification of patients with Alzheimer’s disease. Furthermore, in
some dementia due to inflammation, where a 14-3-3 test might
be false positive, low levels of tau might be helpful in discriminat-
ing forms of neurodegenerative dementia.
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